# Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

> **NCT04133480** · PHASE4 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Lennox-Gastaut Syndrome

## Interventions

- **DRUG:** GWP42003-P

## Key facts

- **NCT ID:** NCT04133480
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase IV study requiring multiple clinic visits when medication is commercially available. The study was withdrawn before any participants were recruited.
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04133480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04133480, "Investigation of Cognitive Outcomes With Cannabidiol Oral Solution". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04133480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*